Viking Therapeutics, Inc. (VKTX) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
VKTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
VKTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export VKTX earnings history in CSV or JSON format
Free sign-in required to download data
Viking Therapeutics, Inc. (VKTX) Earnings Overview
As of May 8, 2026, Viking Therapeutics, Inc. (VKTX) reported trailing twelve-month net income of -$472M, reflecting -215.8% year-over-year growth. The company earned $-4.09 per diluted share over the past four quarters.
Looking at the long-term picture, VKTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$444 in fiscal 2012.
Viking Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including TERN (-$94M net income), PEPG (-$90M net income), KYMR (-$315M net income, -794.4% margin), VKTX has comparable earnings metrics. Compare VKTX vs TERN →
VKTX Earnings vs Peers
Earnings metrics vs comparable public companies
VKTX Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$360M | -227.1% | -$393M | $-3.19 | - | - |
| 2024 | -$110M | -28.0% | -$151M | $-1.01 | - | - |
| 2023 | -$86M | -24.7% | -$101M | $-0.91 | - | - |
| 2022 | -$69M | -25.2% | -$70M | $-0.88 | - | - |
| 2021 | -$55M | -39.2% | -$56M | $-0.70 | - | - |
| 2020 | -$39M | -53.2% | -$43M | $-0.50 | - | - |
| 2019 | -$26M | -16.8% | -$33M | $-0.36 | - | - |
| 2018 | -$22M | -7.2% | -$26M | $-0.38 | - | - |
| 2017 | -$21M | -39.7% | -$19M | $-0.79 | - | - |
| 2016 | -$15M | +37.1% | -$14M | $-0.90 | - | - |
See VKTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VKTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VKTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVKTX — Frequently Asked Questions
Quick answers to the most common questions about buying VKTX stock.
Is VKTX growing earnings?
VKTX EPS fell to $-4.09, with earnings declining -215.8%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-472M.
What are VKTX's profit margins?
Viking Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are VKTX's earnings?
VKTX earnings data spans 2012-2025. The declining earnings trend is -215.8% YoY. Historical data enables comparison across business cycles.